Physician profile
Michael Kurz
NPI 1073705356
$671.15
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $260 · 2021: $41.45 · 2022: $23.99.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $150.58 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.47 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $75.69 | 2019-2020 | |
| Pfizer INC. | $71.45 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $70.24 | 2019-2020 | |
| Lilly USA, LLC | $48.77 | 2019-2020 | |
| Amgen INC. | $32.94 | 2020 | |
| Glaxosmithkline, LLC. | $25.27 | 2019 | |
| Abbott Laboratories | $23.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.78 | 2020 | |
| Astellas Pharma US INC | $19.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.90 | 2020 | |
| Allergan, INC. | $14.16 | 2020 | |
| Abbvie INC. | $11.90 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.49 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kurz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.